Discover key insights from Evolent Health's Q4 2024 earnings call, focusing on 30% revenue growth, contract renegotiations, projections for 2025, ...

Explore key insights from ICON's Q4 2024 earnings call, including bookings growth, digital innovation, and strategic partnerships driving 2025 growth targets.

The following nine stocks are among the best growth stocks to buy for the next 10 years, based on their wide moat, history of ...

Its dollar-based net retention rate stood at an impressive 117% in the previous quarter, as measured by the trailing-12-month ...

Q4 2024 Management View CEO Sandeep Sahai highlighted the company's strong Q4 performance with $126.5 million in revenue, marking 28% year-on-year growth. He emphasized the achievement of a 116% net ...

The broad rally for the S&P 500 index has continued so far in 2025, with a 2% increase for the large-cap U.S. benchmark index through last week. This has some investors continuing to worry that ...

There are no directors' trades from Vanguard Diversified High Growth Index ETF (VDHG). Please use our Changes in directors' interest tool to search for changes & trades across all ASX-listed ...

The budget assumes a nominal GDP growth of 10.1% year-on-year for FY26, and gross tax revenue growth of 10.8%. "Adjusting for the revenue foregone under income tax relief provided to the middle class, ...

You can not sell your investments in this fund for 3 years from the purchase date. Long term capital gain tax will be applicable when you sell your investments after 3 years. Current tax rate is ...

Pune, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Veterinary Therapeutics Market Size & Growth Analysis: “According to SNS Insider, The Veterinary Therapeutics Market size was valued at USD 43.58 Billion ...

It receives an Average Process Pillar rating. The Russell 2000 Growth Index captures the faster-growing half of the Russell 2000 Index. It assigns a composite style score to all stocks in the ...